QRCode



Traders/Users: Online

Biotech Stocks

Fundamental and Chart Analysis

Tech Stocks

For long and short term

Interviews

With NYSE, Nasdaq and OTCBB companies

Contributors

We write opinion articles for the leading companies

Experience

We have more than 10 years of experience in the financial markets

Welcome to bolsaTrading. A website for those who want to be informed about world financial markets.

Our readers could find monthly recommendations of international shares by means of charts as well as fundamentals analysis. Investors buy and/or sell at their own risk. bolsaTrading has zero connection to Wall Street.

3 Reasons to Buy Tenax Therapeutics, Inc

By Jorge Aura

Tenax Therapeutics, Inc (NASDAQ: TENX) According Google Finance, Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Pipeline Overview:




 Source: Tenax Therapeutics Inc

Fundamental Basic Review

Tenax Therapeutics Inc has a market cap of $15,35 million. Its trailing P/E is incalculable, and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. It has a total cash position on its balance sheet of just $19,15 million, and its total debt is at $0. In Tenax therapeutics last quarter, we can see that its operating expenses reached $3,48 million. Based on the operating expenses and the company's cash deducting the current debt from them, we can think that the company would have enough cash for the next four financial quarters or second quarter of 2018.

I find at least four reasons to buy the stock currently:

1.  Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission

On May 16, 2017 Tenax Therapeutics announced to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission.

Tenax met with the FDA on May 10, 2017 to review additional data analyses from the recently completed Phase 3 LEVO-CTS clinical study of levosimendan in cardiac surgery patients at risk of LCOS. The discussion with the FDA built on previously presented primary data analyses of the LEVO-CTS trial that identified a significant interaction in levosimendan’s effectiveness across surgery types enrolled in the study.

Levosimendan NDA Submission is a big potential catalyst for the next weeks.

2. Analysts' price target: $4


  



- On May 18, 2017 Ladenburg Thalmann Upgrades From Neutral to Buy Tenax Therapeutics. The price target market was $2.5 per share.

Analyst Jeffrey Cohen of Ladenburg Thalmann said:

"On May 16th Tenax announced that they had met with the FDA on May 10th to discuss subgroup analysis of the previously announced topline data from their Phase III LEVOCTS Trial. Isolated Coronary Artery Bypass Grafting (CABG) was the largest of the three trial subgroups (563/849 or 66.3%) with the other two being valve replacement with CABG or Valve replacement alone. Yesterday, the company added a new corporate presentation to their website which we believe offers a significant body of evidence related to levosimendan (Simdax) and its effect upon cardiac surgery isolated for CABG.
 Cohen believes that the company will submit additional information from published studies not included in meeting background document within the next 2-6 weeks with expected FDA feedback concerning a filing in July/August. If positive, they would anticipate a filing during Q3-2017."

3. Institutional ownership: 10,51%

Sabby Capital LLC own 1,16 MM shares .

Source: Nasdaq.com



Conclusion:
Tenax Therapeutics is a  tremendously undervalued company. It has a capitalization of $15,35MM and a cash flow of $19,15MM. Levosimendan treatment can provide it with an income of $300MM annually minimum. This enterprise should have a minimum capitalization of $150MM or $5 per share.

*Pipeline overview data sourced from Tenax Therapeutics, Inc, all other data sourced from Nasdaq.com, as well as the web of the previously mentioned company.

Disclosure: Jorge Aura owns shares of Tenax Therapeutics Inc, Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.

4 Reasons to buy Wet Seal Inc

By Jorge Aura

According the company, The Wet Seal, Inc (Nasdaq: WTSL) is a multi-channel specialty retailer. It operates stores that sell fashionable and contemporary apparel and accessory items for female consumers. It operates in two segments, Wet Seal and Arden B. The Wet Seal segment offers fashion apparel and accessories for girls through its Wet Seal stores. The Arden B segment provides contemporary fashion apparel, dresses, sportswear separates, and accessories for the contemporary woman through its Arden B stores. The company also operates in web stores under the wetseal.com and ardenb.com names. As of May 27, 2014, it operated 532 stores in 47 states and Puerto Rico. The Wet Seal, Inc. was founded in 1962.

I find at least four reasons to buy the stock currently:

1.  Historical Revenues vs Historical Quote

WTSL Revenue (TTM) Chart

WTSL Chart
WTSL data by YCharts

Historically with lower sales than at present, the company has had a value per shares much higher.
On July 9, 2013 Wet Seal closed in $5,04 per share. If we see the below chart, the company last year had a higher loss compared to this year.

WTSL Net Income (TTM) Chart

2. The chart mark bounce

MACD is in the time of an onset bullish indication.

3. Analysts' price target: $4
  • On October 11, 2013, Dougherty & Company marks in Wet Seal Inc with a Buy. PT $5.00.
Wet Seal Inc: Analyst stock recommendations
(Source)


4. Insiders are buying 165,120 shares in 2014
The following is a summary of the latest transactions:
  • On April 14, 2014, the director of the company Adam Rothstein bought 20,000 shares at an average price of $1,12.
  • On April 2, 2014, the EVP, store and operations Lesli Gilbert bought 10,000 shares at an average price of $1,36.
Conclusion

Wet Seal Inc is a unique opportunity in the market. The company is undervalued. The insiders buying shows a higher confidence in the company.
*Chart data sourced from stockcharts, all other data sourced from Nasdaq.com as well as the web of the previously mentioned company and yahoo finance.

Disclosure: I am long WTSL. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

4 Reasons To Buy OncoSec Medical

By Jorge Aura

OncoSec Medical (OTCBB: ONCS) develops novel cancer therapeutic products. Its products combine proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics, known as OncoSec Medical System (OMS), which is based on both immunotherapy (ImmunoPulse) and chemotherapy (NeoPulse) agents. According to the company website, Immunopulse and Neopulse are defined as:  
ImmunoPulse delivers instructions to the cell (DNA IL-12) to produce a protein that activates an immune response against cancer cells.
NeoPulse delivers bleomycin, an approved anti-cancer drug that specifically targets and destroys cancer cells.
The most surprising thing is its action method on the two treatments. In the next image, which was provided by the company, you could see how OMS system works.



- Tissue: The generator creates a pulsed electric field that temporarily increases the porosity of cell membranes within the treatment field.
- Poration: The hand-held applicator supplies a series of short-duration electrical pulses of specific voltage through a series of needles.
- Uptake:  Together, the action of the generator and applicator creates a rotating array of pulses     that uniformly subject the targeted cell membranes to electroporation.
Source: Oncosec Medical

Pipeline Overview:

 Source: Oncosec Medical 

Fundamental Basic Review

Oncosec Medical has a market cap of $27.11 million. Its trailing P/E is incalculable, and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. It has a total cash position on its balance sheet of just $8.98 million, and its total debt is at $2.68MM. In Oncosec Medical's last quarter, we can see that its operating expenses reached $1.61 million. Based on the operating expenses and the company's cash deducting the current debt from them, we can think that the company would have enough cash for the next four financial quarters or second quarter of 2014.

I find at least four reasons to buy the stock currently:

1.  Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
On March 25, 2013 Oncosec Medical announced positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial. This data was presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference. This is one of the most important conferences worldwide on studies of melanoma and Cutaneous Malignancies

The data presented were impressive. ImmunoPulse demonstrated a partial or complete response.  ImmunoPulse treated patients showed a 68% and 45% percent of treated lesions demonstrated a durable response at three and six months, respectively.  

To help our readers get an idea of the importance of these results, Amgen (Nasdaq: AMGN) is developing a treatment for melanoma that is currently in phase III trials. The first results provided by the company showed 16% of trial patients on the engineered virus had a durable response compared with 2% of those on the control therapy GM-CSF. 

We hope that Oncosec shows more data from this study at the next ASCO meeting in June, 2013.

2. Analysts' price target: $1.5

  







- On June 21, 2012 without being approved the European designation CE for Neopulse, Roth Capital initiated coverage on OncoSec Medical with a Buy. The price target market was $1.00 per share.

- On May 26, 2011 without being approved the European designation CE for Neopulse and without 3 important phases II treatment of melanoma, carcinoma and lymphoma, Vista Partners initiated coverage on OncoSec Medical with a twelve month target price of $2.90.

Mr. Silver, analyst of Vista Partners said:
"OncoSec's ElectroOncology clinical development pipeline is comprised of cancer treatments intended to address therapeutic needs in multi-billion dollar markets. The company's ElectroChemotherapy has shown in clinical trials to date that it selectively destroys cancer cells while leaving healthy tissue intact, dramatically improving patient quality of life. This provides OncoSec with a considerable potential competitive advantage compared to existing treatment options. OncoSec's ElectroImmunotherapy could prove to be a powerful new approach to treat local and metastatic tumors."
3. Institutional ownership: 14%

- Sabby Capital LLC own 7.32MM shares or 6.24% of total shares.
- Downsview Capital Inc own 5.02MM shares or 4.29% of total shares.
- Ayer Capital Management LP own 4.41MM shares or 3.76% of total shares.
Source: CNN Money

In the OTCBB are few companies with many institutional investors. Oncosec Medical can boast a very high percentage and that will possibly be increased in the coming months with good results in clinical trials.

4. Ten Major Catalysts in 2013

- 2013 — April 15, 2013 Complete enrolment for Phase II melanoma program.
- July 15, 2013 — July 31, 2013 Present interim response data on Phase II melanoma program.
- July 15, 2013 — July 31, 2013 Present long-term PFS data from Phase I melanoma program.
- July 15, 2013 Present interim response data on Phase II Merkel cell carcinoma program.
- July 31, 2013 Complete enrolment for Phase II Merkel cell carcinoma program.
- August 31, 2013 End of Phase II Meeting with FDA for melanoma program.
- September 2013 Present interim data on cutaneous T-cell lymphoma program.
- October 15, 2013 Present final data for Phase II melanoma program.
- October 31, 2013 Present final data for Phase II Merkel cell carcinoma program.
- December 31, 2013 Launch Phase IIB melanoma program.

Source: OncoSec Medical

The next catalysts in OncoSec Medical surely will catapult the stock price.

Conclusion:

OncoSec Medical is a  tremendously undervalued company. It has a capitalization of $27MM and a cash flow of $9MM. Besides, it is carrying out several major studies. Immunopulse and Neopulse treatments can provide it with an income of $500MM annually minimum. This enterprise should have a minimum capitalization of $250MM or $2.5 per share.

*Pipeline overview data sourced from OncoSec Medical, all other data sourced from Nasdaq.com, CNN Money as well as the web of the previously mentioned company.

Disclosure: Jorge Aura owns shares of OncoSec Medical  Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.

Biopharma stocks: 3 Small-caps that have bottomed out in November

By Jorge Aura

All investors know the risks of biotechnology companies. The strong volatility of these companies makes their prices fluctuate in excess. This sector has the peculiarity that offers a high risk but with a possible high gain. Identify pharmaceutical companies that have bottomed out or that are undervalued can be a good investment strategy for medium-term and short-term. In the following table will be able to see the readers, 3 companies which have greatly reduced their quoted prices since on January 3, 2012.

Company January 3, 2012   52-wk low on November 2012          %
Dynavax Technologies Corporation $3.28   $2.22 -32.32%
Horizon Pharma $4.20   $2.03 -51
Somaxon Pharmaceuticals $3.68   $1.29 -64.95%

As you have seen in the upper table these companies have been hit hard during November, 2012. To determine if these companies are undervalued I have made a fundamental analysis of each company.

Dynavax Technologies Corporation (NASDAQ: DVAX) is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences.

Dynavax's lead product candidate is Heplisav. This product candidate is in Phase III to treat adult hepatitis B. Heplisav is an experimental vaccine. On November 15, 2012 Dynavax announced that FDA Vaccines and Related Biological Products Advisory Committee voted thirteen to one that Heplisav data adequately demonstrated immunogenicity. But the same Committee voted eight to five with one abstention that there was insufficient data to adequately support the safety of Heplisav.

Dynavax has a market cap of $489.66 million. Its trailing P/E is incalculable, and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. Dynavax' estimated growth rate for this year is 44.10%. It has a total cash position on its balance sheet of just $148.28 Million. The company announced a revenue on nine months ended September 30 of $7.90MM.


DVAX data by YCharts

This stock plunged from its May high of $5.34 to a recent low in November of $2.22. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $2.91 a share. Look for volume that's tracking in close to or above its three-month average action of 6,547,844 shares.

Horizon Pharma (NASDAQ: HZNP) is a biopharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. On Dec. 3, 2012 The company announced that its product called Rayos (prednisone) delayed release tablets are now available to U.S. physicians to treat a broad range of diseases, including rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma and chronic obstructive pulmonary disease.

Horizon Pharma has a market cap of $141.04 million. Its trailing P/E is incalculable and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. Horizon's estimated growth rate for this year is -788.84%. It has a total cash position on its balance sheet of just $121.33 Million. The company announced a revenue on nine months ended September 30 of $12.88 Million.


HZNP data by YCharts

This stock plunged from its July high of $8.72 to a recent low in November of $2.03. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $2.52 a share. Look for volume that's tracking in close to or above its three-month average action of 933,422 shares.

Somaxon Pharmaceuticals (NASDAQ: SOMX) is a specialty pharmaceutical company that engages in the licensing, development, and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology.

Somaxon has a market cap of $10.63 Million. Its trailing P/E is incalculable and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. Somaxon's estimated growth rate for this year is -10.24%. It has a total cash position on its balance sheet of just $8.5 Million. The company announced a revenue on nine months ended September 30 of $8.22 Million.


SOMX data by YCharts

This stock plunged from its January high of $6.40 to a recent low in November of $1.29. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $1.56 a share. Look for volume that's tracking in close to or above its three-month average action of 59,003 shares.

Disclosure: Jorge Aura has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.